Intracellular mechanisms of TRAIL and its role in cancer therapy

Molecular Cell Biology Research Communications

Volumn 4, Issue 2, 2000, Pages 67-75

  Srivastava, Rakesh K ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; CASPASE; CELL RECEPTOR; FAS ANTIGEN; FAS LIGAND; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P35; PROTEIN SYNTHESIS INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER THERAPY; CYTOLOGY; ENZYME ACTIVATION; HUMAN; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0034478111     PISSN: 15224724     EISSN: None     Source Type: Journal    
DOI: 10.1006/mcbr.2001.0265     Document Type: Article

References (100)

1. CD95(APO-1/Fas)-mediated apptosis: Live and let die
2. Identification and characterization of a new member of the TNF family that induces apoptosis
3. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
4. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis
5. The receptor for the cytotoxic ligand TRAIL
6. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
7. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
8. Characterization of two receptors for TRAIL
9. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
10. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
11. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
12. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
13. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
14. Cell death: TRAIL and its receptors
15. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
16. A novel receptor for Apo2L/TRAIL contains a truncated death domain
17. Death receptors: Signaling and modulation
18. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
19. TRAIL: A molecule with multiple receptors and control mechanisms
20. Apoptosis signaling by death receptors
21. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation
22. Sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cells
23. A crystal structure of an extracellular fragment of human CD40 ligand
24. Expression, purification and crystallization of recombinant human TRAIL
25. Triggering cell death: The crystal structure of Apo2L/TRAIL in a complex with death receptor 5
26. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation
27. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL
28. Temperature sensitive differential affinity of TRAIL for its receptors: DR5 is the highest affinity receptor
29. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems
30. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NFκB pathway
31. Dominant-negative FADD inhibits TNFR60-, Fas/Apo1-and TRAIL-R/Apo2-mediated cell death but not gene induction
32. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis
33. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II
34. FADD is required for DR4- and DR5- mediated apoptosis: Lack of TRAIL- induced apoptosis in FADD-deficient mouse embryonic fibroblasts
35. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade
36. FADD is required for multiple signaling events downstream of the receptor Fas
37. Intracellular mechanisms of TRAIL: Apoptosis through mitochondrial-dependent and -independent pathways
38. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
39. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
40. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
41. Inhibition of death receptor signals by cellular FLIP
42. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
43. Programmed cell death and the caspases
44. Apoptotic pathways: The roads to ruin
45. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation
46. Mitochondria and apoptosis
47. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
48. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3
49. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization
50. L-overexpressing chemotherapy-resistant tumor cells
51. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
52. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
53. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death
54. Cif (Cytochrome c efflux-inducing factor) activity is regulated by Bcl-2 and caspases and correlates with the activation of Bid
55. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis
56. 2-terminal kinase activity, and apoptosis
57. Control of programmed cell death by the baculovirus genes p35 and IAP
58. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases
59. Expression of baculovirus P35 prevents cell death in Drosophila
60. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes
61. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins
62. A conserved family of cellular genes related to the baculovirus IAP gene and encoding apoptosis inhibitors
63. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors
64. Apoptotic suppression by baculovirus P35 involves cleavage by and inhibition of a virus-induced CED-3/ICE-like protease
65. CrmA, a poxvirus-encoded serpin, inhibits cytotoxic T-lymphocyte-mediated apoptosis
66. CrmA-inhibitable cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein during Fas- and tumor necrosis factor-induced apoptosis
67. Signal transduction in Fas-mediated apoptosis
68. X-linked IAP is a direct inhibitor of cell-death proteases
69. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization
70. Bax directly induces release of cytochrome c from isolated mitochondria
71. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
72. Human IAP-like protein regulates programmed cell death downstream of Bcl-xL and cytochrome c
73. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs
74. The death receptors
75. The mitochondrial death/life regulator in apoptosis and necrosis
76. Two CD95 (APO-1/Fas) signaling pathways
77. Bcl-2-mediated drug resistance: Inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription
78. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis
79. The Bcl-2 protein family: Arbiters of cell survival
80. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death
81. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents
82. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis
83. Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis
84. Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis
85. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
86. Activation of p38 mitogen-activated protein kinase and caspases in UVB-induced apoptosis of human keratinocyte HaCaT cells
87. Molecular determinants of response to TRAIL in killing of normal and cancer cells
88. The TRAIL to selective tumor death
89. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
90. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NFκB and AP-1
91. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
92. Molecular determinants of response to TRAIL in killing of normal and cancer cells
93. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
94. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
95. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes
96. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
97. Expression of TRAIL (Apo2L), DR4 (TRAIL receptor 1), DR5 (TRAIL receptor 2) and TRID (TRAIL receptor 3) genes in multidrug resistant human acute myeloid leukemia cell lines that overexpress MDR 1 (HL60/Tax) or MRP (HL60/AR)
98. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
99. Safety and antitumor activity of recombinant soluble Apo2 ligand
100. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha